Combined androgen blockade for advanced prostatic carcinoma

Hormonal therapy has been mainstay of treatment for advanced forms of prost ate cancer for over 50 y. The choice of hormonal therapy for carcinoma of t he prostate depends not only on the desired progression-free and overall su rvival but also on the patient's quality of Life, treatment costs and treat ment toxicities. At the present time, several important questions have been raised over optimal treatment modalities for advanced prostate cancer. The optimal form of this therapy is still an enigma.